⚕ GalenOps field
←

708-1347

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
708 (USA) · Dr. Kim
consented 2013-04-20

AEs
8
Serious
0
Dropout signal
–

Adverse events

moderate assessed

Moderate APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-06-13 (study day 55.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE ERYTHEMA — outcome: RECOVERED/RESOLVED; onset 2013-06-13 (study day 55.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE SWELLING — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-06-13 (study day 55.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE SWELLING — outcome: RECOVERED/RESOLVED; onset 2013-06-13 (study day 55.0); relationship: PROBABLE

moderate assessed

Moderate ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-06-13 (study day 55.0); relationship: PROBABLE

moderate assessed

Moderate ERYTHEMA — outcome: RECOVERED/RESOLVED; onset 2013-06-13 (study day 55.0); relationship: PROBABLE

mild assessed

Mild PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-06-13 (study day 55.0); relationship: PROBABLE

mild assessed

Mild PRURITUS — outcome: RECOVERED/RESOLVED; onset 2013-06-13 (study day 55.0); relationship: PROBABLE

Data queries

No data queries.